allergytalk

Episode 28: Is IBS a Type of Food Allergy? Nov/Dec 2021

For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

 

Metabolic Changes During Anaphylaxis Vary by Triggers and Severity

 

Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers.

 

Is IBS Caused by Local Food Allergy in the Intestine?

 

Local immune response to food antigens drives meal-induced abdominal pain.

 

Biologics: To Stop or Not to Stop, That Is the Question

 

Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.

 

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 26: Do Airborne Peanuts Cause Allergic Reactions? July/Aug 2021

For today’s episode we will be reviewing articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Articles Reviewed:

When an asthma patient doesn’t respond to biologic, what should we do?

Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.

Can we reduce lung function loss in asthma?

Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.

Airborne peanut doesn’t cause clinical significant reactions

Peanuts in the air - clinical and experimental studies.

 

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, Alladapt, Novartis

Episode 25: Is Cefazolin Safe in Penicillin Allergic Patients? May/June 2021

For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Articles Reviewed:

AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma

The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.

Cefazolin Should Be Used in Most Penicillin Allergic Patients

Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin: A Systematic Review and Meta-analysis.

 

Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine

 

Cardiovascular changes during peanut-induced allergic reactions in human subjects.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

AllergyTalk Episode 32: How Does the Atopic March Differ in Black and White Children?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Hernandez-Trujillo: 

Speaker Takeda, CSL

Advisory boards Takeda, Regeneron, Sanofi

Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 31: The Presentation of an Inborn Error of Immunity Is Not Always Infection!

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis

Episode 30: Is COVID Vaccine Skin Testing Useful?

Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.

Differences in oral food challenge reaction severity based on increasing age in a pediatric population.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Severe Pediatric Asthma Miniseries - Episode 3

Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Severe Pediatric Asthma Miniseries - Episode 2

Episode 2:       Severe pediatric asthma-evaluation of the child, diagnostic testing, assessing steroid side effects

 

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Severe Pediatric Asthma Miniseries - Episode 1

Episode 1: Severe pediatric asthma-burden of disease, adherence issues, and comorbidities

 

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

CRSwNP Miniseries: Episode 3

Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations.

 

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose
Anjeni Keswani, MD: Nothing to disclose

 

This podcast series is supported by Sanofi Regeneron.